Contact
searchSearch
HMP Global
Login

Diffuse Large B-Cell Lymphoma (ASH 2022) Basic Listing

Updates in Diffuse Large B-Cell Lymphoma
From the ASH Annual Meeting & Exposition

Conference Coverage
Real-World ctDNA Monitoring Shows MRD Clearance Predicts Relapse Risk and Survival Outcomes for DLBCL: HOVON-902 Analysis
12/11/2025
Emily Estrada
Serial ctDNA MRD monitoring among patients with DLBCL may predict relapse risk and survival outcomes, according to real-world study results presented at the 2025 ASH Annual Meeting & Exposition.
Serial ctDNA MRD monitoring among patients with DLBCL may predict relapse risk and survival outcomes, according to real-world study results presented at the 2025 ASH Annual Meeting & Exposition.
Serial ctDNA MRD monitoring...
12/11/2025
Oncology
Conference Coverage
Circulating Tumor DNA Utility for Predicting Outcomes for Patients With Aggressive and Indolent Lymphomas: Real-World Analysis
12/11/2025
Gina Tomaine
At the ASH 2025 Annual Meeting & Exposition, real-world data data was presented on the strong prognostic utility of ctDNA as a biomarker to inform treatment across indolent and aggressive subtypes of lymphoma.
At the ASH 2025 Annual Meeting & Exposition, real-world data data was presented on the strong prognostic utility of ctDNA as a biomarker to inform treatment across indolent and aggressive subtypes of lymphoma.
At the ASH 2025 Annual Meeting &...
12/11/2025
Oncology
Conference Coverage
Odronextamab Plus CHOP Demonstrates High Response Rates and Manageable Safety for Previously Untreated DLBCL: First Results From OLYMPIA-3 Trial
12/03/2025
Emily Estrada
Odronextamab plus CHOP chemotherapy achieved high response rates and manageable toxicity for previously untreated DLBCL, according to data to be presented at the 2025 ASH Annual Meeting.
Odronextamab plus CHOP chemotherapy achieved high response rates and manageable toxicity for previously untreated DLBCL, according to data to be presented at the 2025 ASH Annual Meeting.
Odronextamab plus CHOP...
12/03/2025
Oncology
Conference Coverage
Epcoritamab Monotherapy Demonstrates High Response Rates and Durable MRD Negativity in Elderly, Chemotherapy-Ineligible 1L DLBCL Patients: Interim Results from EPCORE DLBCL-3
12/03/2025
Emily Estrada
Fixed-duration subcutaneous epcoritamab monotherapy demonstrated promising efficacy, early and sustained MRD negativity, and manageable safety among patients with DLBCL, according to data to be presented at the 2025 ASH Annual Meeting.
Fixed-duration subcutaneous epcoritamab monotherapy demonstrated promising efficacy, early and sustained MRD negativity, and manageable safety among patients with DLBCL, according to data to be presented at the 2025 ASH Annual Meeting.
Fixed-duration subcutaneous...
12/03/2025
Oncology
Conference Coverage
Zanubrutinib Plus R-CHOP Therapy Shows Promising Efficacy, Acceptable Safety Among Patients With DLBCL Harboring Specific Gene Subtypes
12/02/2025
Emily Estrada
Zanubrutinib and R-CHOP therapy demonstrated encouraging anti-tumor activity and acceptable tolerability among patients with diffuse large B-cell lymphoma with certain genetic alterations, according to data presented at the 2025 ASH Annual...
Zanubrutinib and R-CHOP therapy demonstrated encouraging anti-tumor activity and acceptable tolerability among patients with diffuse large B-cell lymphoma with certain genetic alterations, according to data presented at the 2025 ASH Annual...
Zanubrutinib and R-CHOP therapy...
12/02/2025
Oncology
Conference Coverage
Subcutaneous Mosunetuzumab Shows Efficacy and Safety Among Elderly, Chemotherapy-Ineligible Patients With DLBCL: MorningSun Trial
12/02/2025
Emily Estrada
According to data presented at the 2025 ASH Annual Meeting, fixed-duration subcutaneous mosunetuzumab monotherapy achieved high response rates with manageable toxicity among elderly/unfit patients with diffuse large B-cell lymphoma.
According to data presented at the 2025 ASH Annual Meeting, fixed-duration subcutaneous mosunetuzumab monotherapy achieved high response rates with manageable toxicity among elderly/unfit patients with diffuse large B-cell lymphoma.
According to data presented at...
12/02/2025
Oncology
Conference Coverage
Retreatment With R-CHOP-Like Therapy Effective in Late-Relapse DLBCL
12/07/2024
Meagan Thistle
In patients with late-relapse DLBCL, a retreatment strategy with R-CHOP-like therapy is a reasonable option and results in durable remission in a high proportion of patients, according to a retrospective study.
In patients with late-relapse DLBCL, a retreatment strategy with R-CHOP-like therapy is a reasonable option and results in durable remission in a high proportion of patients, according to a retrospective study.
In patients with late-relapse...
12/07/2024
Oncology
Conference Coverage
Real-World Efficacy of Bispecific Antibodies for Patients With Relapsed or Refractory Large B-Cell Lymphomas
12/05/2024
Stephanie Holland
According to results from a retrospective study, the bispecific antibodies epcoritamab and glofitamab demonstrated worse outcomes among patients with relapsed or refractory large b-cell lymphomas in the real-world setting, compared with trial...
According to results from a retrospective study, the bispecific antibodies epcoritamab and glofitamab demonstrated worse outcomes among patients with relapsed or refractory large b-cell lymphomas in the real-world setting, compared with trial...
According to results from a...
12/05/2024
Oncology
Conference Coverage
Time of CAR-T Cell Therapy Failure May Predict Outcomes of Bispecific Antibody Therapy Among Patients With Relapsed or Refractory Large B-Cell Lymphoma
12/05/2024
Allison Casey
According to a retrospective, real-world study presented at the 2024 ASH Annual Meeting & Exposition, the timing of CAR-T cell therapy failure may predict the outcomes for bispecific antibody therapies for patients with relapsed/refractory...
According to a retrospective, real-world study presented at the 2024 ASH Annual Meeting & Exposition, the timing of CAR-T cell therapy failure may predict the outcomes for bispecific antibody therapies for patients with relapsed/refractory...
According to a retrospective,...
12/05/2024
Oncology
Conference Coverage
CD22-Directed CAR-T Therapy Provides Durable Remission and Long-Term Survival in Large B-Cell Lymphoma
12/05/2024
Among patients with large B-cell lymphoma progressing after CD19-directed CAR T-cell therapy, treatment with CD22-Directed CAR T-cells provided durable remissions and long-term survival after 3 years, according to follow-up data presented at...
Among patients with large B-cell lymphoma progressing after CD19-directed CAR T-cell therapy, treatment with CD22-Directed CAR T-cells provided durable remissions and long-term survival after 3 years, according to follow-up data presented at...
Among patients with large B-cell...
12/05/2024
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use